{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T22:11:49Z","timestamp":1771539109088,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T00:00:00Z","timestamp":1562976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T00:00:00Z","timestamp":1562976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s11136-019-02245-2","type":"journal-article","created":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T17:02:15Z","timestamp":1563037335000},"page":"2979-2988","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Adapting traditional content validation methods to fit purpose: an example with a novel video assessment and training materials in Duchenne muscular dystrophy (DMD)"],"prefix":"10.1007","volume":"28","author":[{"given":"Michelle K.","family":"White","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mindy","family":"Leffler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitlin","family":"Rychlec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"McSherry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linsey","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Kosinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,13]]},"reference":[{"key":"2245_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.addr.2015.05.008","volume":"87","author":"R Kole","year":"2015","unstructured":"Kole, R., & Krieg, A. M. (2015). Exon skipping therapy for Duchenne muscular dystrophy. Advanced Drug Delivery Reviews,\n                           87, 104\u2013107. \n                    https:\/\/doi.org\/10.1016\/j.addr.2015.05.008\n                    \n                  .","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"3","key":"2245_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1136\/jmedgenet-2015-103387","volume":"53","author":"A Aartsma-Rus","year":"2016","unstructured":"Aartsma-Rus, A., Ginjaar, I. B., & Bushby, K. (2016). The importance of genetic diagnosis for Duchenne muscular dystrophy. Journal of Medical Genetics,\n                           53(3), 145\u2013151. \n                    https:\/\/doi.org\/10.1136\/jmedgenet-2015-103387\n                    \n                  .","journal-title":"Journal of Medical Genetics"},{"issue":"10","key":"2245_CR3","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S1474-4422(09)70211-X","volume":"8","author":"M Kinali","year":"2009","unstructured":"Kinali, M., Arechavala-Gomeza, V., Feng, L., et al. (2009). Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: A single-blind, placebo-controlled, dose-escalation, proof-of-concept study. The Lancet Neurology,\n                           8(10), 918\u2013928. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(09)70211-X\n                    \n                  .","journal-title":"The Lancet Neurology"},{"issue":"3","key":"2245_CR4","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/ana.23528","volume":"71","author":"JR Mendell","year":"2012","unstructured":"Mendell, J. R., Shilling, C., Leslie, N. D., et al. (2012). Evidence-based path to newborn screening for Duchenne muscular dystrophy. Annals of Neurology,\n                           71(3), 304\u2013313. \n                    https:\/\/doi.org\/10.1002\/ana.23528\n                    \n                  .","journal-title":"Annals of Neurology"},{"issue":"1","key":"2245_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0960-8966(91)90039-U","volume":"1","author":"AE Emery","year":"1991","unstructured":"Emery, A. E. (1991). Population frequencies of inherited neuromuscular diseases\u2014A world survey. Neuromuscular Disorders: NMD,\n                           1(1), 19\u201329.","journal-title":"Neuromuscular Disorders: NMD"},{"key":"2245_CR6","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.2147\/NDT.S93873","volume":"12","author":"JK Mah","year":"2016","unstructured":"Mah, J. K. (2016). Current and emerging treatment strategies for Duchenne muscular dystrophy. Neuropsychiatric Disease and Treatment,\n                           12, 1795\u20131807. \n                    https:\/\/doi.org\/10.2147\/NDT.S93873\n                    \n                  .","journal-title":"Neuropsychiatric Disease and Treatment"},{"issue":"10","key":"2245_CR7","doi-asserted-by":"publisher","first-page":"18168","DOI":"10.3390\/molecules201018168","volume":"20","author":"MS Falzarano","year":"2015","unstructured":"Falzarano, M. S., Scotton, C., Passarelli, C., & Ferlini, A. (2015). Duchenne muscular dystrophy: From diagnosis to therapy. Molecules (Basel, Switzerland),\n                           20(10), 18168\u201318184. \n                    https:\/\/doi.org\/10.3390\/molecules201018168\n                    \n                  .","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"1","key":"2245_CR8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1152\/physrev.00007.2015","volume":"96","author":"DG Allen","year":"2016","unstructured":"Allen, D. G., Whitehead, N. P., & Froehner, S. C. (2016). Absence of dystrophin disrupts skeletal muscle signaling: Roles of Ca2+, reactive oxygen species, and nitric oxide in the development of muscular dystrophy. Physiological Reviews,\n                           96(1), 253\u2013305. \n                    https:\/\/doi.org\/10.1152\/physrev.00007.2015\n                    \n                  .","journal-title":"Physiological Reviews"},{"issue":"4","key":"2245_CR9","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mus.21544","volume":"41","author":"CM McDonald","year":"2010","unstructured":"McDonald, C. M., Henricson, E. K., Han, J. J., et al. (2010). The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle and Nerve,\n                           41(4), 500\u2013510. \n                    https:\/\/doi.org\/10.1002\/mus.21544\n                    \n                  .","journal-title":"Muscle and Nerve"},{"issue":"6","key":"2245_CR10","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1469-8749.2011.03939.x","volume":"53","author":"A Mayhew","year":"2011","unstructured":"Mayhew, A., Cano, S., Scott, E., Eagle, M., Bushby, K., & Muntoni, F. (2011). Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Developmental Medicine and Child Neurology,\n                           53(6), 535\u2013542. \n                    https:\/\/doi.org\/10.1111\/j.1469-8749.2011.03939.x\n                    \n                  .","journal-title":"Developmental Medicine and Child Neurology"},{"issue":"11","key":"2245_CR11","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/dmcn.12213","volume":"55","author":"A Mayhew","year":"2013","unstructured":"Mayhew, A., Mazzone, E. S., Eagle, M., et al. (2013). Development of the performance of the upper limb module for Duchenne muscular dystrophy. Developmental Medicine and Child Neurology,\n                           55(11), 1038\u20131045. \n                    https:\/\/doi.org\/10.1111\/dmcn.12213\n                    \n                  .","journal-title":"Developmental Medicine and Child Neurology"},{"issue":"3","key":"2245_CR12","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/mus.880040304","volume":"4","author":"MH Brooke","year":"1981","unstructured":"Brooke, M. H., Griggs, R. C., Mendell, J. R., Fenichel, G. M., Shumate, J. B., & Pellegrino, R. J. (1981). Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle and Nerve,\n                           4(3), 186\u2013197. \n                    https:\/\/doi.org\/10.1002\/mus.880040304\n                    \n                  .","journal-title":"Muscle and Nerve"},{"issue":"9","key":"2245_CR13","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.nmd.2014.06.228","volume":"24","author":"C McDonald","year":"2014","unstructured":"McDonald, C., Reha, A., Elfring, G. L., Peltz, S. W., & Spiegel, R. (2014). TP 5: Timed function tests and other physical function outcomes in Ataluren-treated patients with nonsense mutation Duchenne Muscular Dystrophy (nmDMD). Neuromuscular Disorders,\n                           24(9), 861.","journal-title":"Neuromuscular Disorders"},{"issue":"4","key":"2245_CR14","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00415-017-8406-2","volume":"264","author":"C Otto","year":"2017","unstructured":"Otto, C., Steffensen, B. F., H\u00f8jberg, A., et al. (2017). Predictors of health-related quality of life in boys with Duchenne muscular dystrophy from six European countries. Journal of Neurology,\n                           264(4), 709\u2013723. \n                    https:\/\/doi.org\/10.1007\/s00415-017-8406-2\n                    \n                  .","journal-title":"Journal of Neurology"},{"issue":"2","key":"2245_CR15","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/dmcn.13277","volume":"59","author":"K Klingels","year":"2017","unstructured":"Klingels, K., Mayhew, A. G., Mazzone, E. S., et al. (2017). Development of a patient-reported outcome measure for upper limb function in Duchenne muscular dystrophy: DMD Upper Limb PROM. Developmental Medicine and Child Neurology,\n                           59(2), 224\u2013231. \n                    https:\/\/doi.org\/10.1111\/dmcn.13277\n                    \n                  .","journal-title":"Developmental Medicine and Child Neurology"},{"issue":"12","key":"2245_CR16","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.nmd.2015.09.012","volume":"25","author":"E Landfeldt","year":"2015","unstructured":"Landfeldt, E., Mayhew, A., Eagle, M., et al. (2015). Development and psychometric analysis of the Duchenne muscular dystrophy Functional Ability Self-Assessment Tool (DMDSAT). Neuromuscular Disorders: NMD,\n                           25(12), 937\u2013944. \n                    https:\/\/doi.org\/10.1016\/j.nmd.2015.09.012\n                    \n                  .","journal-title":"Neuromuscular Disorders: NMD"},{"key":"2245_CR17","volume-title":"Guidance for industry patient-reported outcome measures: Use in medical product development to support labeling claims","author":"US Food and Drug Administration","year":"2009","unstructured":"US Food and Drug Administration. (2009). Guidance for industry patient-reported outcome measures: Use in medical product development to support labeling claims. Silver Spring: US Food and Drug Administration."},{"issue":"8","key":"2245_CR18","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick, D. L., Burke, L. B., Gwaltney, C. J., et al. (2011). Content validity\u2014Establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: Part 2\u2014Assessing respondent understanding. Value in Health,\n                           14(8), 978\u2013988. \n                    https:\/\/doi.org\/10.1016\/j.jval.2011.06.013\n                    \n                  .","journal-title":"Value in Health"},{"issue":"6","key":"2245_CR19","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jval.2015.08.006","volume":"18","author":"MK Walton","year":"2015","unstructured":"Walton, M. K., Powers, J. H., Hobart, J., et al. (2015). Clinical outcome assessments: Conceptual foundation-report of the ISPOR clinical outcomes assessment\u2014emerging good practices for outcomes research task force. Value in Health,\n                           18(6), 741\u2013752. \n                    https:\/\/doi.org\/10.1016\/j.jval.2015.08.006\n                    \n                  .","journal-title":"Value in Health"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-019-02245-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11136-019-02245-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-019-02245-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T23:25:13Z","timestamp":1594509913000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11136-019-02245-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,13]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["2245"],"URL":"https:\/\/doi.org\/10.1007\/s11136-019-02245-2","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,13]]},"assertion":[{"value":"3 July 2019","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MKW, KR, and MK are full-time employees of Optum and received research funding from Sarepta Therapeutics, Inc. to conduct the study. ML and CM are full-time employees of Casimir LLC and received research funding from Sarepta Therapeutics, Inc. to conduct the study. CJ is a full-time employee of CJ Jones Strategy & Communications, Inc. and a shareholder in iTakeControl Health Inc. and received research funding from Sarepta Therapeutics, Inc. to conduct a study in parallel with the research described in this publication. LW is a full-time employee of the study sponsor, Sarepta Therapeutics, Inc. and owns stock in the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The caregiver interview informed consent form, protocol, and discussion guide were approved by the New England Independent Review Board (IRB#120170139). All caregivers who participated in the qualitative interviews provided written consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}